Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:03 2022-12-07 pm EST
104.81 USD   +0.91%
12/02Reckitt expects U.S. infant formula shortage until spring
RE
12/01Reckitt expects U.S. infant formula shortage until spring
RE
12/01Enfamil maker Reckitt sees formula shortage continuing until Spring
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ABBOTT LABORATORIES : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

09/15/2022 | 04:05pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories' ("Abbott") Board of Directors.


Item 5.03       Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.


On September 15, 2022, Abbott's Board of Directors amended the first sentence of Article III, Section 2 of Abbott's by-laws to provide that Abbott's Board of Directors shall consist of thirteen persons, effective as of September 15, 2022. Abbott's by-laws previously provided that the Board of Directors consisted of twelve persons.



Item 9.01       Financial Statements and Exhibits.



  Exhibit No. Exhibit




           3.1          By-Laws of Abbott Laboratories, as amended and restated
                      effective September 15, 2022.




         104          Cover Page Interactive Data File (the cover page XBRL tags
                      are embedded in the Inline XBRL document).

© Edgar Online, source Glimpses

All news about ABBOTT LABORATORIES
12/02Reckitt expects U.S. infant formula shortage until spring
RE
12/01Reckitt expects U.S. infant formula shortage until spring
RE
12/01Enfamil maker Reckitt sees formula shortage continuing until Spring
RE
11/25Ypsomed, CamDiab Roll Out Automated Insulin Dosing on Abbott's Glucose Monitoring Syste..
MT
11/21Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable a..
CI
11/17Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
PR
11/10Becton Dickinson expects fiscal 2023 COVID test sales to drag
RE
11/07MedTech Market Leaders Share Their Long-Term Business Strategy at CECP's CEO Investor F..
AQ
11/02NZ's a2 Milk gets temporary approval to export infant milk formula to U.S
RE
11/01ABBOTT LABORATORIES Management's Discussion and Analysis of Financial Condition and Re..
AQ
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 43 181 M - -
Net income 2022 6 845 M - -
Net Debt 2022 4 483 M - -
P/E ratio 2022 27,1x
Yield 2022 1,78%
Capitalization 183 B 183 B -
EV / Sales 2022 4,34x
EV / Sales 2023 4,63x
Nbr of Employees 113 000
Free-Float 87,2%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 104,81 $
Average target price 116,15 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-25.53%182 744
MEDTRONIC PLC-25.49%102 304
BECTON, DICKINSON AND COMPANY0.29%69 846
DEXCOM, INC.-12.97%45 544
HOYA CORPORATION-21.30%35 092
AMERISOURCEBERGEN CORPORATION28.14%35 024